214 related articles for article (PubMed ID: 15243533)
1. Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy.
Myers SA; Ahearn GS; Angelica Selim M; Tapson VF
J Am Acad Dermatol; 2004 Jul; 51(1):98-102. PubMed ID: 15243533
[TBL] [Abstract][Full Text] [Related]
2. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
3. Treprostinil for the treatment of pulmonary arterial hypertension.
Torres F; Rubin LJ
Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
[TBL] [Abstract][Full Text] [Related]
4. Prostanoid therapy for pulmonary arterial hypertension.
Badesch DB; McLaughlin VV; Delcroix M; Vizza CD; Olschewski H; Sitbon O; Barst RJ
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):56S-61S. PubMed ID: 15194179
[TBL] [Abstract][Full Text] [Related]
5. Prostacyclin therapy for pulmonary arterial hypertension: new directions.
Gomberg-Maitland M; Preston IR
Semin Respir Crit Care Med; 2005 Aug; 26(4):394-401. PubMed ID: 16121316
[TBL] [Abstract][Full Text] [Related]
6. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
7. How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension?
Barst R
Int J Clin Pract Suppl; 2010 Nov; (168):23-32. PubMed ID: 20939843
[TBL] [Abstract][Full Text] [Related]
8. Rapid switch from intravenous epoprostenol to intravenous treprostinil in patients with pulmonary arterial hypertension.
Sitbon O; Manes A; Jais X; Pallazini M; Humbert M; Presotto L; Paillette Ld; Zaccardelli D; Davis G; Jeffs R; Simonneau G; Galie N
J Cardiovasc Pharmacol; 2007 Jan; 49(1):1-5. PubMed ID: 17261956
[TBL] [Abstract][Full Text] [Related]
9. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.
Badesch DB; McGoon MD; Barst RJ; Tapson VF; Rubin LJ; Wigley FM; Kral KM; Raphiou IH; Crater GD
J Rheumatol; 2009 Oct; 36(10):2244-9. PubMed ID: 19723905
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of disease-specific health-related quality of life in patients with pulmonary arterial hypertension.
Zlupko M; Harhay MO; Gallop R; Shin J; Archer-Chicko C; Patel R; Palevsky HI; Taichman DB
Respir Med; 2008 Oct; 102(10):1431-8. PubMed ID: 18617379
[TBL] [Abstract][Full Text] [Related]
12. Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin).
Klings ES; Hill NS; Ieong MH; Simms RW; Korn JH; Farber HW
Arthritis Rheum; 1999 Dec; 42(12):2638-45. PubMed ID: 10616012
[TBL] [Abstract][Full Text] [Related]
13. Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension. A case report.
Badalian SS; Silverman RK; Aubry RH; Longo J
J Reprod Med; 2000 Feb; 45(2):149-52. PubMed ID: 10710749
[TBL] [Abstract][Full Text] [Related]
14. Continuous intravenous epoprostenol in pulmonary hypertension: the Israel experience.
Bendayan D; Fink G; Aravot D; Ygla M; Bendov I; Bliden L; Nir A; Kramer MR
Isr Med Assoc J; 2002 Apr; 4(4):255-8. PubMed ID: 12001697
[TBL] [Abstract][Full Text] [Related]
15. [Epoprostenol in the treatment of portopulmonary hypertension].
Culafić D; Culafić-Vojinović V; Jesić R
Srp Arh Celok Lek; 2003; 131(5-6):271-4. PubMed ID: 14692137
[TBL] [Abstract][Full Text] [Related]
16. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol.
Fix OK; Bass NM; De Marco T; Merriman RB
Liver Transpl; 2007 Jun; 13(6):875-85. PubMed ID: 17539008
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.
Farber HW; Graven KK; Kokolski G; Korn JH
J Rheumatol; 1999 May; 26(5):1195-6. PubMed ID: 10332990
[TBL] [Abstract][Full Text] [Related]
18. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension.
Findlay JY; Plevak DJ; Krowka MJ; Sack EM; Porayko MK
Liver Transpl Surg; 1999 Sep; 5(5):362-5. PubMed ID: 10477835
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment, tolerability, and survival with sub-cutaneous treprostinil for severe pulmonary hypertension.
Sadushi-Koliçi R; Skoro-Sajer N; Zimmer D; Bonderman D; Schemper M; Klepetko W; Glatz J; Jakowitsch J; Lang IM
J Heart Lung Transplant; 2012 Jul; 31(7):735-43. PubMed ID: 22480725
[TBL] [Abstract][Full Text] [Related]
20. Epoprostenol Therapy for Pulmonary Arterial Hypertension.
Akagi S; Nakamura K; Matsubara H; Ogawa A; Sarashina T; Ejiri K; Ito H
Acta Med Okayama; 2015; 69(3):129-36. PubMed ID: 26101188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
